Liver Disease Pathophysiology

Introduction to Liver Disease

Liver disease manifests in patients through a limited number of ways regardless of the diverse pathogenic agents and processes that can affect the organ. These diseases are categorized as acute or chronic, focal or diffuse, mild or severe, and reversible or irreversible. Most acute cases, such as those caused by viral hepatitis, are so mild they never reach medical attention, with symptoms like fatigue, loss of appetite, and nausea often mistaken for the flu. However, severe acute injury can lead to cholestasis (impaired bile formation) or massive liver cell death and progressive multi-organ failure. This latter condition, known as acute liver failure or fulminant hepatic failure, carries a high mortality rate, though survival has improved with emergency liver transplantation.

The spectrum of liver diseases is broad and includes inherited hyperbilirubinemia (Gilbert, Crigler–Najjar, Dubin–Johnson, and Rotor syndromes), viral hepatitis (types A, B, C, D, and E, along with Epstein–Barr and others), and immune-mediated diseases (primary biliary cirrhosis, autoimmune hepatitis, and sclerosing cholangitis). Genetic disorders like alpha-1-antitrypsin deficiency, Hemochromatosis, and Wilson disease also impact liver health. Other categories include alcoholic liver disease, nonalcoholic fatty liver disease (NAFLD), and liver involvement in systemic diseases such as sarcoidosis, amyloidosis, and celiac disease. Drug-induced injury can present in hepatocellular, cholestatic, or mixed patterns, while vascular injuries include Budd–Chiari syndrome and venoocclusive disease. Liver injury may resolve, become recurrent (chronic hepatitis), or lead to cirrhosis—the ultimate consequence of progressive injury where the liver becomes hard, shrunken, and nodular with impaired function.

Anatomy, Histology, and Cell Biology

The liver is located in the right upper quadrant of the abdomen, situated in the peritoneal space just below the diaphragm and protected by the rib cage. It is anatomically divided into the right and left lobes, with the right lobe containing the posterior caudate and inferior quadrate segments. Functionally, it is divided into four sectors and further into eight segments based on portal blood flow. In an adult, the liver weighs approximately $1400\,g$ and is encased in a fibrous capsule. It receives nearly $25\%$ of the cardiac output, totaling approximately $1500\,mL/min$ of blood flow. This flow comes from two sources: the portal vein, which provides nutrient-rich venous flow from the small intestine and hormones from the pancreas (insulin, glucagon, somatostatin, and pancreatic polypeptide), and the hepatic artery, which provides oxygenation. These vessels converge, and blood exits via central veins (terminal veins or hepatic venules) into the hepatic vein and the inferior vena cava.

The parenchyma is organized into plates of hepatocytes supported by reticuloendothelial cells, which make up about $30\%$ of all liver cells. The plates are typically one cell thick and are separated by vascular spaces called sinusoids where arterial and portal blood mix. The reticuloendothelial system includes endothelial cells lining the sinusoids, Kupffer cells (specialized macrophages), and stellate cells (lipocytes), which store fat and vitamin A. Kupffer cells account for about $33\%$ of reticuloendothelial cells but only $2\%$ to $10\%$ of total liver protein due to their smaller size. These cells perform phagocytosis, secrete cytokines, and communicate with hepatocytes; their dysfunction contributes to necrosis in acute disease and fibrosis in chronic disease.

Concepts of Liver Organization and Zonation

Liver architecture has traditionally been described in terms of the lobule, a hexagonal array of hepatocyte plates organized around a central vein, with portal triads (containing a portal venule, hepatic arteriole, and bile canaliculus) at the corners. Hepatocytes adjacent to the portal triad are known as the limiting plate, the disruption of which is a diagnostic marker for certain immune-mediated liver diseases. Physiologically, the acinus concept is more useful, describing liver tissue centered around the portal venule and hepatic arteriole. In this model, blood flow creates functional zones: Zone 1 hepatocytes are the first to receive blood and are exposed to the highest oxygen and nutrient concentrations. They are active in gluconeogenesis, oxidative energy metabolism, and urea synthesis. Zone 3 hepatocytes, located near the central vein, are the last to receive blood and have the lowest oxygen levels. They are active in glycolysis and lipogenesis. Zone 2 hepatocytes exhibit intermediate attributes. This zonation means direct poisons typically affect Zone 1, while toxins generated by metabolism affect Zone 3. Zone 3 is also most susceptible to injury from hypoxia.

Hepatocytes are polarized cells with distinct surfaces performing specific tasks. The apical surface forms the wall of the bile canaliculus for bile transport and excretion, while the basolateral surface faces the sinusoids for uptake from and secretion into the bloodstream. These domains are separated by tight junctions. Dysfunction in one domain eventually affects the other; for instance, cholestasis (an apical disorder) eventually impairs basolateral uptake of bilirubin. The liver possesses a massive reserve capacity and the ability to regenerate fully differentiated cells through proliferation stimulated by growth factors like $HGF$ and $TGF-\alpha$, and cytokines such as $TNF$, $IL-1$, and $IL-6$. This allows for complete recovery from acute injury if the patient survives the initial phase.

Liver Blood Flow and Physiology

Portal blood flow is a low-pressure circuit, normally under a hydrostatic pressure of approximately $10\,mm\,Hg$. The liver's low resistance is facilitated by fenestrations (spaces between endothelial cells) and the lack of a typical basement membrane between endothelial cells and hepatocytes. These fenestrations allow plasma and proteins free access to the hepatocyte surface while excluding red blood cells. In cirrhosis, these features are altered, increasing portal pressure and leading to portal-to-systemic shunting, where blood bypasses the liver's filtering system.

The liver's functions are grouped into four categories: energy metabolism, protein synthesis, solubilization/transport/storage, and protective/clearance functions. In carbohydrate metabolism, the liver manages glucose consumption and storage (glycogen synthesis, glycolysis) postprandially when the insulin-to-glucagon ratio is high. During fasting or stress, it performs glycogenolysis and gluconeogenesis to maintain blood glucose. Protein metabolism involves oxidative deamination and transamination to shuffle amino groups and the urea cycle to convert toxic ammonia into urea. Lipid metabolism includes the synthesis of $80\%$ of the body's cholesterol from acetate and the processing of triglycerides. Lipoproteins mediate this: chylomicrons carry dietary fat, VLDLs distribute triglycerides to tissues, and HDLs scavenge excess cholesterol for return to the liver.

Solubilization, Transport, and Storage Functions

Bile is a detergent-like substance synthesized by the liver to solubilize insoluble substances for transport. Bile acids are recycled via the enterohepatic circulation: they are synthesized in hepatocytes, secreted into the biliary tract, used in the duodenum to aid fat digestion, and reabsorbed in the terminal ileum. Portal blood returns them to the liver, where the sodium taurocholate cotransporter ($Ntcp$) returns them to the hepatocyte cytosol. Drug metabolism occurs primarily in the smooth endoplasmic reticulum through biotransformations. Phase I reactions involve oxidation-reduction to add a reactive "handle," while Phase II reactions involve covalent attachment to water-soluble carriers like glucuronic acid or glutathione. Phase I can sometimes create toxic intermediates that damage the cell if Phase II is impaired.

The liver also produces binding proteins for minerals and hormones. Transferrin is an iron-binding protein that, upon binding iron, attaches to the transferrin receptor for internalization. In the acidic environment of the endosome, iron is released and stored in the cytoplasm as ferritin, while the empty transferrin recycles back to the bloodstream. This prevents free iron from acting as an oxidant or nutrient for pathogens. Other storage functions include vitamin A in lipocytes. The liver also participates in clearance via Kupffer cells, which use receptors (Fc, C3, and carbohydrate) to remove bacteria, antigens, and debris. Hepatocytes use distinct receptors, like the asialoglycoprotein receptor, to clear damaged plasma proteins.

Clinical Assessment of Liver Function

Serum enzymes $AST$ and $ALT$ are markers of hepatocyte necrosis rather than direct measures of function. True functional tests include measuring serum albumin, clotting factors, and bilirubin. Albumin has a long half-life of $18$ to $20\,days$, making it a better indicator of chronic rather than acute function. The prothrombin time ($PT$) measures clotting factor levels but is insensitive, only becoming abnormal after an $80\%$ loss of synthetic capacity. Bilirubin provides a measure of cholestasis; direct (conjugated) versus indirect (unconjugated) levels help distinguish between liver-intrinsic cholestasis and external obstruction.

Severity is graded using the modified Child–Pugh score, which uses five parameters: ascites, encephalopathy, bilirubin, albumin, and $PT$ prolongation. A score of $5$ to $6$ is Grade A, $7$ to $9$ is Grade B, and $10$ to $15$ is Grade C. Survival rates correlate with these grades: Grade A ($100$ to $85\%$), Grade B ($80$ to $60\%$), and Grade C ($45$ to $35\%$). The Model for End-Stage Liver Disease (MELD) score is used for transplant prioritization and is calculated as $3.78 \times \ln(\text{serum bilirubin in mg/dL}) + 11.2 \times \ln(\text{INR}) + 9.57 \times \ln(\text{serum creatinine in mg/dL}) + 6.43$. The MELD-Na score improves accuracy by incorporating serum sodium ($Na$) and is calculated as $\text{MELD} + 1.32 \times (137 - Na) - [0.033 \times \text{MELD} \times (137 - Na)]$.

Acute Hepatitis

Acute hepatitis is an inflammatory process causing liver cell death via necrosis or apoptosis. Common causes include viruses (HAV, HBV, HCV, HDV, HEV) and toxins like ethanol and isoniazid. HAV is an RNA virus spread fecal-orally, often causing mild disease, but sometimes fulminant failure; recovery provides lifelong immunity. HBV is a DNA virus spread by blood or sexual contact; damage is caused by the host immune response (cytolytic T lymphocytes) rather than the virus itself. HCV is an RNA virus with high rates ($60$ to $85\%$) of progression to chronic disease. HDV requires HBV to infect and increases the risk of fulminant disease. HEV is fecal-oral and exceptionally dangerous for pregnant women, with mortality rates reaching $15$ to $20\%$ in the third trimester.

Clinical presentation of acute hepatitis includes three phases: the pre-icteric phase (prodrome) with malaise, nausea, and right upper quadrant pain; the icteric phase with jaundice, dark urine, and light stools; and the convalescent phase where symptoms resolve but laboratory tests remains abnormal. Histology typically shows ballooning degeneration, portal inflammation, and Kupffer cell prominence. In severe cases, bridging hepatic necrosis links portal and central areas. Fulminant hepatitis results in "acute yellow atrophy" with massive necrosis. Toxic hepatitis can be dose-dependent (e.g., acetaminophen) or idiosyncratic. Acetaminophen toxicity is dangerous at levels as low as $2.5\,g$ in susceptible individuals (e.g., those with alcoholism whose Phase I enzymes are induced and Phase II glutathione is depleted).

Chronic Hepatitis and NAFLD

Chronic hepatitis is defined as inflammation and necrosis persisting for more than $6\,months$. It is graded and staged using systems like Batts–Ludwig or Metavir. Causes include viral persistence, drugs, and autoimmune factors. Autoimmune hepatitis is more common in women ($75\%$), characterized by hyperglobulinemia and autoantibodies. Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in Western countries, associated with obesity and metabolic syndrome. It ranges from simple steatosis (NAFL) to nonalcoholic steatohepatitis (NASH), where inflammation increases the risk of cirrhosis. The pathogenesis involves insulin resistance leading to lipid accumulation and subsequent oxidative stress.

Cholestatic autoimmune diseases include primary biliary cholangitis (PBC), which involves the destruction of small intralobular bile ducts and the presence of anti-mitochondrial antibodies, and primary sclerosing cholangitis (PSC), characterized by biliary strictures often associated with inflammatory bowel disease. Pathologically, mild chronic hepatitis shows inflammation confined to the portal triad, while severe cases exhibit "piecemeal necrosis" (erosion of the limiting plate) and bridging fibrosis.

Cirrhosis and Portal Hypertension

Cirrhosis involves irreversible distortion of liver architecture through injury, fibrosis, and nodular regeneration. Alcohol is the leading cause in the US, while HBV and HCV lead globally. Fibrosis is driven by the activation of stellate cells into myofibroblasts, which produce excessive extracellular matrix. Fibrosis occurs in two stages: initially reversible dense collagen formation, followed by irreversible subendothelial cross-links and regenerating nodules. Cirrhosis is classified as micronodular (nodules < 3\,mm) or macronodular (> 3\,mm).

Portal hypertension (gradient > 5\,mm\,Hg) results from increased vascular resistance. Clinical manifestations include ascites, which is diagnosed by a serum-to-ascites albumin gradient (SAAG) of $1.1\,g/dL$ or more. Three theories explain ascites: the underfill/vasodilatation hypothesis (central volume diversion), the splanchnic vasodilatation hypothesis (nitric oxide-induced systemic vasodilation), and the overflow hypothesis (inappropriate renal sodium retention). Hepatorenal syndrome is a functional kidney failure caused by intense renal vasoconstriction. Type 1 is rapidly progressive (creatinine doubles to > 2.5\,mg/dL in < 2\,weeks), while Type 2 is slower and associated with diuretic-resistant ascites.

Systemic Manifestations of Advanced Liver Disease

Gastroesophageal varices develop when the portal gradient exceeds $12\,mm\,Hg$; they carry a high risk of rupture and mortality ($30\%$ per episode). Hepatic encephalopathy is a neuropsychiatric syndrome caused by toxins like ammonia bypassing the liver through shunts. Early signs include sleep-wake cycle reversal, progressing to asterixis, confusion, and coma. Precipitants include GI bleeding, infection, and high protein intake. Treatment involves lactulose, which acidifies the gut to trap ammonia as $NH_4^+$, and the antibiotic rifaximin.

Hepatocellular carcinoma (HCC) is a major complication, with a $5$-year risk of $5$ to $30\%$ in cirrhotic patients. HBV accounts for $50\%$ of global cases. Pulmonary complications include hepatopulmonary syndrome (triad of failure, hypoxemia, and vascular dilation), portopulmonary hypertension, and hepatic hydrothorax. Physical signs of cirrhosis include spider angiomas, palmar erythema, and Dupuytren contractures, largely due to estrogen excess from decreased clearance and increased peripheral aromatization of androgens. Feminization in men manifests as gynecomastia and testicular atrophy.